Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data at the 36th EORTC-NCI-AACR Symposium, ENA 2024, taking place in Barcelona, Spain from October 23 to 25, on the potential of its cyclin E1-directed molecular glue degraders for the treatment of CCNE1-amplified solid tumors. The data being presented demonstrate that Monte Rosa’s MGD degrades cyclin E1 with a high level of selectivity, sparing other closely related proteins, including other cyclins, and cyclin-dependent kinases. The data also showed that a cyclin E1-directed MGD led to downstream pathway inhibition and induced tumor growth suppression and regression preferentially in CCNE1-amplified and over-expressing tumor cell lines and xenograft models. The Company continues to perform preclinical research in order to progress the program towards a development candidate nomination.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Questions or Comments about the article? Write to editor@tipranks.com